Biovica launches rights issue of up to 97,303,733 B-shares, targeting about SEK 29.2 million
Bitget2026/10/06 13:05Biovica’s board resolved to launch a rights issue of up to 97,303,733 B-shares, targeting about SEK 29.2 million before costs. The decision was subject to an extraordinary general meeting, which later endorsed the rights issue on Sept. 30. Subscription runs Oct. 7–21, with subscription rights trading Oct. 7–16. Paid subscribed shares (BTA) are set to trade Oct. 7–28, with results expected Oct. 23. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
- Biovica’s board resolved to launch a rights issue of up to 97,303,733 B-shares, targeting about SEK 29.2 million before costs.
- The decision was subject to an extraordinary general meeting, which later endorsed the rights issue on Sept. 30.
- Subscription runs Oct. 7–21, with subscription rights trading Oct. 7–16.
- Paid subscribed shares (BTA) are set to trade Oct. 7–28, with results expected Oct. 23.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.